Use of dianhydrogalactitol and analogs and derivatives thereof to treat recurrent malignant glioma or progressive secondary brain tumor
Methods and compositions suitable for the treatment of malignancies such as recurrent glioma and progressive secondary brain tumor are disclosed. These methods employ a hexitol derivative such as dianhydrogalactitol, a derivative or analog of dianhydrogalactitol, diacetyldianhydrogalactitol, or a derivative or analog of diacetyldianhydrogalactitol. The compositions can include such hexitol derivatives.
1. A method for the treatment of recurrent glioma or progressive secondary brain tumor comprising the administration of a therapeutically effective quantity of a hexitol derivative selected from the group consisting of dianhydrogalactitol and diacetyldianhydrogalactitol, wherein the recurrent glioma is resistant to temozolomide and bevacizumab, and wherein the hexitol derivative is administered at a therapeutically effective dose of up to 40 mg/m 2 for 3 days followed by a nadir/recovery period of 18 to 21 days.
2. A method to improve the efficacy and/or reduce the side effects of the administration of a hexitol derivative for treatment of recurrent glioma or progressive secondary brain tumor comprising the steps of:
(a) identifying at least one factor or parameter associated with the efficacy and/or occurrence of side effects of the administration of the hexitol derivative for treatment of the malignancy; and
(b) modifying the factor or parameter to improve the efficacy and/or reduce the side effects of the administration of the hexitol derivative for treatment of the malignancy, wherein the hexitol derivative is dianhydrogalactitol, and wherein the recurrent glioma is resistant to temozolomide and bevacizumab and the factor or parameter is one or more of dose modification, route of administration, and/or schedule of administration; and
wherein the hexitol derivative is administered at a therapeutically effective dose of up to 40 mg/m 2 for 3 days followed by a nadir/recovery period of 18 to 21 days.
3. The method of claim 1 , wherein the dosing is up to a cumulative effective quantity of 240 mg/m 2 in a 33-day treatment cycle.
4. The method of claim 3 , wherein the dosing is up to a cumulative effective quantity of 240 mg/m 2 in a 33-day treatment cycle.
5. The method of claim 1 , wherein the hexitol derivative is administered on days 1, 2 and 3.
6. A method for the treatment of recurrent glioma or progressive secondary brain tumor comprising the administration of a therapeutically effective quantity of a hexitol derivative selected from the group consisting of dianhydrogalactitol and diacetyldianhydrogalactitol, wherein the recurrent glioma is resistant to temozolomide and bevacizumab, and wherein the hexitol derivative is administered at a therapeutically effective dose of up to 40 mg/m 2 for 3 days followed by a nadir/recovery period of 18 to 21 days, and wherein the dosing is up to a cumulative effective quantity of 240 mg/m 2 in a 33-day treatment cycle.
7. The method of claim 6 , wherein the hexitol derivative is administered on days 1, 2, and 3.
8. A method to improve the efficacy and/or reduce the side effects of the administration of a hexitol derivative for treatment of recurrent glioma or progressive secondary brain tumor comprising the steps of:
(a) identifying at least one factor or parameter associated with the efficacy and/or occurrence of side effects of the administration of the hexitol derivative for treatment of the malignancy; and
(b) modifying the factor or parameter to improve the efficacy and/or reduce the side effects of the administration of the hexitol derivative for treatment of the malignancy, wherein the hexitol derivative is dianhydrogalactitol, and wherein the recurrent glioma is resistant to temozolomide and bevacizumab and the factor or parameter is one or more of dose modification, route of administration, and/or schedule of administration; and
wherein the hexitol derivative is administered at a therapeutically effective dose of up to 40 mg/m 2 for 3 days followed by a nadir/recovery period of 18 to 21 days, and wherein the dosing is up to a cumulative effective quantity of 240 mg/m 2 in a 33-day treatment cycle.